UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286420987941-1756286420987941

2021

Volltextzugriff (PDF)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Journal of neurology, 2020-10, Vol.267 (10), p.2851-2864

2020

Volltextzugriff (PDF)

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study

International journal of MS care, 2017-05, Vol.19 (3), p.141-147

2017

Volltextzugriff (PDF)

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

Neuro-oncology advances, 2023-01, Vol.5 (1), p.vdac183-vdac183

2023

Volltextzugriff (PDF)

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax

mAbs, 2016-10, Vol.8 (7), p.1417-1424

2016

Volltextzugriff (PDF)

Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis

Expert review of clinical pharmacology, 2014-01, Vol.7 (1), p.9-19

2014

Volltextzugriff (PDF)

Matching-Adjusted Comparison of Daclizumab Beta vs Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis (P1.356)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Escherichia coli Secretion of an Active Chimeric Antibody Fragment

Science (American Association for the Advancement of Science), 1988-05, Vol.240 (4855), p.1041-1043

1988

Volltextzugriff (PDF)

Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study (P6.390)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.953-953

2018

Volltextzugriff (PDF)

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2

Cancer research (Chicago, Ill.), 1990-09, Vol.50 (17), p.5234-5239

1990

Volltextzugriff (PDF)

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta

International journal of MS care, 2017-05, Vol.19 (3), p.141-147

2017

Volltextzugriff (PDF)

Secretion of Functional Antibody and Fab Fragment from Yeast Cells

Proceedings of the National Academy of Sciences - PNAS, 1988-11, Vol.85 (22), p.8678-8682

1988

Volltextzugriff (PDF)

Chimeric Mouse-Human IgG1 Antibody that Can Mediate Lysis of Cancer Cells

Proceedings of the National Academy of Sciences - PNAS, 1987-05, Vol.84 (10), p.3439-3443

1987

Volltextzugriff (PDF)

Production of anti-erythrocyte antibodies by leukemic and nonleukemic b cells in chronic lymphocytic leukemia patients

Leukemia & lymphoma, 1996, Vol.20 (5-6), p.465-469

1996

Volltextzugriff (PDF)

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax

mAbs, 2016, Vol.8 (7), p.1417-1424

2016

Volltextzugriff (PDF)

Multiple mRNA species with distinct 3′ termini are transcribed from the β2-microglobulin gene

Nature (London), 1983-03, Vol.302 (5907), p.449-452

1983

Volltextzugriff (PDF)

Analysis of a Drosophila tRNA gene cluster: Two tRNA Leu genes contain intervening sequences

Cell, 1981, Vol.23 (1), p.251-259

1981

Volltextzugriff (PDF)

Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells

Gene, 1987, Vol.54 (1), p.33-40

1987

Volltextzugriff (PDF)

Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells

Journal of immunotherapy, 1992-01, Vol.11 (1), p.30-39

1992

Volltextzugriff (PDF)

Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities

Human antibodies, 1991-06, Vol.2 (2), p.84-93

1991

Volltextzugriff (PDF)

Partnership to solo

Medical economics, 2008-01, Vol.85 (1), p.12

Robinson, Randy R

2008

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(62)

Publikationsform

Sprache

Englisch
(77)

Erscheinungsjahr

n.n

Thema

Science & Technology
(56)
Life Sciences & Biomedicine
(45)
Humans
(33)
Male
(20)
Biological And Medical Sciences
(19)
Female
(17)
Adult
(11)
Animals
(11)
Fundamental And Applied Biological Sciences. Psychology
(11)
Middle Aged
(11)
Medical Sciences
(9)
Neurosciences & Neurology
(9)
Multidisciplinary Sciences
(7)
Science & Technology - Other Topics
(7)
Aged
(6)
Clinical Neurology
(6)
Daclizumab
(6)
Immunology
(6)
Multiple Sclerosis
(6)
Time Factors
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax

Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis

Matching-Adjusted Comparison of Daclizumab Beta vs Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis (P1.356)

Escherichia coli Secretion of an Active Chimeric Antibody Fragment

Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study (P6.390)

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2

Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta

Secretion of Functional Antibody and Fab Fragment from Yeast Cells

Chimeric Mouse-Human IgG1 Antibody that Can Mediate Lysis of Cancer Cells

Corrigendum to “Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration” [J. Autoimmun. 21 (2004) 283–293]

Production of anti-erythrocyte antibodies by leukemic and nonleukemic b cells in chronic lymphocytic leukemia patients

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax

Multiple mRNA species with distinct 3′ termini are transcribed from the β2-microglobulin gene

Analysis of a Drosophila tRNA gene cluster: Two tRNA Leu genes contain intervening sequences

Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells

Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells

Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities

Partnership to solo

Suchergebnisse filtern